Kamada Ltd (NASDAQ:KMDA) will issue its Q415 quarterly earnings data on Tuesday, February 2nd. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $27.10 million for the quarter.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by $0.09. The company had revenue of $16.10 million for the quarter, compared to the consensus estimate of $18.67 million. On average, analysts expect Kamada to post $-0.43 EPS for the current fiscal year and $-0.15 EPS for the next fiscal year.

A number of research firms have weighed in on KMDA. Zacks Investment Research upgraded shares of Kamada from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 14th. Jefferies Group reduced their price objective on shares of Kamada from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, November 13th.

Shares of Kamada Ltd (NASDAQ:KMDA) opened at 3.69 on Friday. The company’s market cap is $131.19 million. The company’s 50-day moving average is $4.09 and its 200-day moving average is $3.85. Kamada Ltd has a one year low of $3.19 and a one year high of $5.15.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

12 Month Chart for NASDAQ:KMDA

Receive News & Ratings for Kamada Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd and related companies with MarketBeat.com's FREE daily email newsletter.